董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kristiina Vuori | 女 | Director | 55 | 6.67万美元 | 0.39 | 2023-09-11 |
| R. Erik Holmlin | 男 | President, Chief Executive Officer and Director | 55 | 111.27万美元 | 1.91 | 2023-09-11 |
| Albert Luderer | 男 | Director | 74 | 9.57万美元 | 0.40 | 2023-09-11 |
| Christopher Twomey | 男 | Director | 64 | 6.84万美元 | 0.40 | 2023-09-11 |
| Hannah Mamuszka | 女 | Director | 46 | 5.59万美元 | 0.41 | 2023-09-11 |
| Yvonne Linney | 女 | Director | 61 | 5.50万美元 | 0.40 | 2023-09-11 |
| Vincent J. Wong | 男 | Director | 51 | 3.48万美元 | 未持股 | 2023-09-11 |
| Aleksandar Rajkovic | -- | Director | 59 | 5.34万美元 | 未持股 | 2023-09-11 |
| David L. Barker | 男 | Chairman, Director | 81 | 7.34万美元 | 0.40 | 2023-09-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. Erik Holmlin | 男 | President, Chief Executive Officer and Director | 55 | 111.27万美元 | 1.91 | 2023-09-11 |
| Mark Oldakowski | 男 | Chief Operating Officer | 50 | 75.63万美元 | 0.82 | 2023-09-11 |
| Gulsen Kama | 女 | Chief Financial Officer | -- | 未披露 | 未持股 | 2023-09-11 |
| Alka Chaubey | 女 | Chief Medical Officer | 50 | 75.63万美元 | 0.79 | 2023-09-11 |
| Jonathan Dixon | 男 | General Counsel | 48 | 未披露 | 未持股 | 2023-09-11 |
董事简历
中英对照 | 中文 | 英文- Kristiina Vuori
-
Kristiina Vuori获得学士学位和博士学位，从2014年7月开始担任WebMD董事。Vuori博士从2010年开始一直担任伯纳姆医学研究所（Sanford-Burnham Medical Research Institute）的总裁，从2013年开始担任其临时首席执行官，领导该研究所的学术、科学与综合运营。该研究所是一个非盈利研究机构，致力于研究疾病的最根本的分子层面的原因，并设计未来的创新疗法，其主要的研究项目在癌症、神经退行性疾病、糖尿病与传染病、炎症与儿童疾病领域。Vuori博士还担任该研究所的波林与斯坦利·福斯特主席，并担任该研究所的美国国家癌症研究所（National Cancer Institute，NCI）——指定的癌症中心的教授，这是一项交叉学科的基础与转化研究活动，其调动超过400位的科学家进行研究。从2005年到2013年，Vuori博士还领导了癌症中心。Vuori博士在芬兰的奥卢大学（University of Oulu）获得医学博士学位与博士学位。完成其实习与住院医师实习后，从1992年到1995年，她在伯纳姆医学研究所（Sanford-Burnham）获得博士后学习，并于1996年被任命担任教员。Vuori博士在国家卫生研究所（NIH）、美国国家癌症研究所（NCI）、美国国防部（Department of Defense）、对抗癌症梦之队（Stand Up To Cancer Dream Team）与加州癌症研究计划（California Cancer Research Programs）获得诸多研究经费资助与奖励。她还担任美国国家癌症研究所与其他癌症机构的多个顾问职位，包括美国国家癌症研究所的发展疗法计划、战略科学中心计划与国家癌症咨询委员会的顾问职位。此外，Vuori博士担任美国癌症研究协会（American Association for Cancer Research）、加州再生医学研究院（California Institute for Regenerative Medicine）与加州乳腺癌研究理事会（California Breast Cancer Research Council）。她还担任科学期刊与机构科学顾问委员会的诸多编辑委员会职位。
Kristiina Vuori,has served on Bionano Genomics, Inc. board of directors since May 2019. Since January 1995, Dr. Vuori has served as Professor, and since January 2010 as Pauline and Stanley Foster Distinguished Chair, at the National Cancer Institute-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute, or the Institute, a non-profit research organization with programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. In addition, Dr. Vuori served as President and member of the board of directors of the Institute from January 2010 to June 2022, and as the Institute's interim CEO from January 2013 to September 2014, and from September 2017 to June 2020. She served as the Institute's EVP for Scientific Affairs in 2008-2010, as Director of the Cancer Center in 2005-2013, and as Deputy Director of the Cancer Center in 2003-2005. Dr. Vuori has also served as a member of the board of directors of Inhibrx, Inc., a public biotechnology company, since October 2021, of Forian, Inc., a public health data analytics company, since March 2021, and of Sio Gene Therapies, Inc., a public gene therapy company, since October 2020. In addition, Dr. Vuori served on the board of directors of WebMD from July 2014 to September 2017 (when it was acquired by KKR & Co. Inc.) and of the California Institute for Regenerative Medicine, a governmental research institute, from January 2011 to December 2022. Dr. Vuori earned her M.D. and Ph.D. from the University of Oulu, Finland. - Kristiina Vuori获得学士学位和博士学位，从2014年7月开始担任WebMD董事。Vuori博士从2010年开始一直担任伯纳姆医学研究所（Sanford-Burnham Medical Research Institute）的总裁，从2013年开始担任其临时首席执行官，领导该研究所的学术、科学与综合运营。该研究所是一个非盈利研究机构，致力于研究疾病的最根本的分子层面的原因，并设计未来的创新疗法，其主要的研究项目在癌症、神经退行性疾病、糖尿病与传染病、炎症与儿童疾病领域。Vuori博士还担任该研究所的波林与斯坦利·福斯特主席，并担任该研究所的美国国家癌症研究所（National Cancer Institute，NCI）——指定的癌症中心的教授，这是一项交叉学科的基础与转化研究活动，其调动超过400位的科学家进行研究。从2005年到2013年，Vuori博士还领导了癌症中心。Vuori博士在芬兰的奥卢大学（University of Oulu）获得医学博士学位与博士学位。完成其实习与住院医师实习后，从1992年到1995年，她在伯纳姆医学研究所（Sanford-Burnham）获得博士后学习，并于1996年被任命担任教员。Vuori博士在国家卫生研究所（NIH）、美国国家癌症研究所（NCI）、美国国防部（Department of Defense）、对抗癌症梦之队（Stand Up To Cancer Dream Team）与加州癌症研究计划（California Cancer Research Programs）获得诸多研究经费资助与奖励。她还担任美国国家癌症研究所与其他癌症机构的多个顾问职位，包括美国国家癌症研究所的发展疗法计划、战略科学中心计划与国家癌症咨询委员会的顾问职位。此外，Vuori博士担任美国癌症研究协会（American Association for Cancer Research）、加州再生医学研究院（California Institute for Regenerative Medicine）与加州乳腺癌研究理事会（California Breast Cancer Research Council）。她还担任科学期刊与机构科学顾问委员会的诸多编辑委员会职位。
- Kristiina Vuori,has served on Bionano Genomics, Inc. board of directors since May 2019. Since January 1995, Dr. Vuori has served as Professor, and since January 2010 as Pauline and Stanley Foster Distinguished Chair, at the National Cancer Institute-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute, or the Institute, a non-profit research organization with programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. In addition, Dr. Vuori served as President and member of the board of directors of the Institute from January 2010 to June 2022, and as the Institute's interim CEO from January 2013 to September 2014, and from September 2017 to June 2020. She served as the Institute's EVP for Scientific Affairs in 2008-2010, as Director of the Cancer Center in 2005-2013, and as Deputy Director of the Cancer Center in 2003-2005. Dr. Vuori has also served as a member of the board of directors of Inhibrx, Inc., a public biotechnology company, since October 2021, of Forian, Inc., a public health data analytics company, since March 2021, and of Sio Gene Therapies, Inc., a public gene therapy company, since October 2020. In addition, Dr. Vuori served on the board of directors of WebMD from July 2014 to September 2017 (when it was acquired by KKR & Co. Inc.) and of the California Institute for Regenerative Medicine, a governmental research institute, from January 2011 to December 2022. Dr. Vuori earned her M.D. and Ph.D. from the University of Oulu, Finland.
- R. Erik Holmlin
-
R.Erik Holmlin自2011年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。Holmlin从2010年6月到2011年2月担任GenVault Corporation（一家私人生物样本管理解决方案公司）总裁和首席执行官。此前，Holmlin博士曾担任Domain Associates（一家专注的生命科学风险投资公司）的常驻企业家；Exiqon A/S（一家公开上市的RNA研究解决方案公司）的首席商务官；它被Becton Dickinson and Company收购；以及Harvard University的国家卫生研究院博士后研究员。直到2016年6月，Holmlin博士担任Nanosphere，Inc.的董事，该公司是一家公开上市的分子诊断公司，随后被公开上市的生物测试公司路明克斯公司收购。Holmlin博士在西方学院（Occidental College）获得化学学士学位，在加州理工学院（California Institute of Technology）获得化学博士学位，在加州大学伯克利分校（University of California，Berkeley）和哥伦比亚大学（Columbia University）获得MBA学位。
R. Erik Holmlin,has served as Bionano Genomics, Inc. President and Chief Executive Officer and as a member of Bionano Genomics, Inc. board of directors since January 2011. Dr. Holmlin has also served as a member of the board of directors of Innovatus Life Sciences Acquisition Corp, a blank check company seeking to effect a business combination with one or more businesses, since March 2021. From June 2010 to February 2011, Dr. Holmlin served as president and Chief Executive Officer of GenVault Corporation, a private biosample management solutions company. Previously, Dr. Holmlin held positions as an entrepreneur in residence at Domain Associates, LLC, a dedicated life sciences venture capital firm; Chief Commercial Officer of Exiqon A/S, a publicly traded RNA research solutions company; founder and executive at GeneOhm Sciences, Inc., which was acquired by Becton, Dickinson and Company; and a National Institutes of Health postdoctoral fellow at Harvard University. Dr. Holmlin received his B.S. in Chemistry from Occidental College, his Ph.D. in Chemistry from the California Institute of Technology and MBAs from University of California, Berkeley and Columbia University. - R.Erik Holmlin自2011年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。Holmlin从2010年6月到2011年2月担任GenVault Corporation（一家私人生物样本管理解决方案公司）总裁和首席执行官。此前，Holmlin博士曾担任Domain Associates（一家专注的生命科学风险投资公司）的常驻企业家；Exiqon A/S（一家公开上市的RNA研究解决方案公司）的首席商务官；它被Becton Dickinson and Company收购；以及Harvard University的国家卫生研究院博士后研究员。直到2016年6月，Holmlin博士担任Nanosphere，Inc.的董事，该公司是一家公开上市的分子诊断公司，随后被公开上市的生物测试公司路明克斯公司收购。Holmlin博士在西方学院（Occidental College）获得化学学士学位，在加州理工学院（California Institute of Technology）获得化学博士学位，在加州大学伯克利分校（University of California，Berkeley）和哥伦比亚大学（Columbia University）获得MBA学位。
- R. Erik Holmlin,has served as Bionano Genomics, Inc. President and Chief Executive Officer and as a member of Bionano Genomics, Inc. board of directors since January 2011. Dr. Holmlin has also served as a member of the board of directors of Innovatus Life Sciences Acquisition Corp, a blank check company seeking to effect a business combination with one or more businesses, since March 2021. From June 2010 to February 2011, Dr. Holmlin served as president and Chief Executive Officer of GenVault Corporation, a private biosample management solutions company. Previously, Dr. Holmlin held positions as an entrepreneur in residence at Domain Associates, LLC, a dedicated life sciences venture capital firm; Chief Commercial Officer of Exiqon A/S, a publicly traded RNA research solutions company; founder and executive at GeneOhm Sciences, Inc., which was acquired by Becton, Dickinson and Company; and a National Institutes of Health postdoctoral fellow at Harvard University. Dr. Holmlin received his B.S. in Chemistry from Occidental College, his Ph.D. in Chemistry from the California Institute of Technology and MBAs from University of California, Berkeley and Columbia University.
- Albert Luderer
-
Albert Luderer自2011年10月以来一直担任我们的董事会成员。Luderer博士目前担任Indi Molecular，Inc.的首席执行官兼董事会成员，该公司是一家合成抗体技术公司，并担任前列腺管理诊断公司的董事会执行主席。Luderer博士在技术开发、运营和业务发展领域拥有超过30年的执行领导角色的经验。Luderer博士在德鲁大学（Drew University）获得动物学学士学位，并在罗格斯大学（Rutgers University）获得免疫化学硕士学位和免疫原学博士学位。
Albert Luderer,has served on Bionano Genomics, Inc. board of directors since October 2011. Since September 2013, Dr. Luderer has served as the Chief Executive Officer and a member of the board of directors of Indi Molecular, Inc., a private synthetic antibody technology company. He has also served as the Executive Chairman of the board of directors of Prostate Management Diagnostics Inc., a non-profit cancer research company, since January 2016, and as the Chairman of the board of directors and member of the compensation committee of AllerGenis, LLC, a private diagnostic company, since September 2021. Dr. Luderer previously served as the Chief Executive Officer of Integrated Diagnostics, Inc., a private molecular diagnostics company, from March 2010 to June 2018, when it was sold to Biodesix, Inc. Dr. Luderer has over 30 years of experience in executive leadership roles in the areas of technology development, operations and business development. Dr. Luderer received his B.A. in Zoology from Drew University and his M.S. in Immunochemistry and Ph.D. in Immunogenics from Rutgers University. - Albert Luderer自2011年10月以来一直担任我们的董事会成员。Luderer博士目前担任Indi Molecular，Inc.的首席执行官兼董事会成员，该公司是一家合成抗体技术公司，并担任前列腺管理诊断公司的董事会执行主席。Luderer博士在技术开发、运营和业务发展领域拥有超过30年的执行领导角色的经验。Luderer博士在德鲁大学（Drew University）获得动物学学士学位，并在罗格斯大学（Rutgers University）获得免疫化学硕士学位和免疫原学博士学位。
- Albert Luderer,has served on Bionano Genomics, Inc. board of directors since October 2011. Since September 2013, Dr. Luderer has served as the Chief Executive Officer and a member of the board of directors of Indi Molecular, Inc., a private synthetic antibody technology company. He has also served as the Executive Chairman of the board of directors of Prostate Management Diagnostics Inc., a non-profit cancer research company, since January 2016, and as the Chairman of the board of directors and member of the compensation committee of AllerGenis, LLC, a private diagnostic company, since September 2021. Dr. Luderer previously served as the Chief Executive Officer of Integrated Diagnostics, Inc., a private molecular diagnostics company, from March 2010 to June 2018, when it was sold to Biodesix, Inc. Dr. Luderer has over 30 years of experience in executive leadership roles in the areas of technology development, operations and business development. Dr. Luderer received his B.A. in Zoology from Drew University and his M.S. in Immunochemistry and Ph.D. in Immunogenics from Rutgers University.
- Christopher Twomey
-
Christopher Twomey自2018年7月以来一直担任我们的董事会成员。自2013年8月以来，Twomey先生一直担任Tandem DiabetesCare，Inc.（一家医疗设备公司）的董事兼审计委员会主席。Twomey从1990年3月到2007年6月在Biosite Incorporated（一家医疗诊断公司）担任多个职位，包括高级副总裁，财务和首席财务官。Twomey从1981年10月到1990年3月担任Ernst&Young，LLP审计经理。2006年3月至2018年11月，Twomey先生担任味觉技术公司Senomyx，Inc.的董事，该公司于2018年11月被Firmenich收购。从2006年7月到2014年3月，Twomey先生还担任CadencePharmaceuticals，Inc.的董事兼审计委员会主席，该公司是一家专业制药公司，于2014年被马林克罗制药有限公司收购。Twomey先生在加州大学圣巴巴拉分校（University of California at Santa Barbara）获得商业经济学学士学位。
Christopher Twomey,has served on Bionano Genomics, Inc. board of directors since July 2018. Since August 2013, Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a public medical device company. From March 1990 to June 2007, Mr. Twomey served in various roles, including as Senior Vice President, Finance and Chief Financial Officer, at Biosite Incorporated, a medical diagnostics company. From October 1981 to March 1990, Mr. Twomey served as an audit manager for Ernst & Young, LLP. Mr. Twomey served as a director of Senomyx, Inc., a taste technologies company, from March 2006 to November 2018 (when it was acquired by Firmenich SA). From July 2006 to March 2014, Mr. Twomey also served as a director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey received his B.A. in Business Economics from the University of California at Santa Barbara. - Christopher Twomey自2018年7月以来一直担任我们的董事会成员。自2013年8月以来，Twomey先生一直担任Tandem DiabetesCare，Inc.（一家医疗设备公司）的董事兼审计委员会主席。Twomey从1990年3月到2007年6月在Biosite Incorporated（一家医疗诊断公司）担任多个职位，包括高级副总裁，财务和首席财务官。Twomey从1981年10月到1990年3月担任Ernst&Young，LLP审计经理。2006年3月至2018年11月，Twomey先生担任味觉技术公司Senomyx，Inc.的董事，该公司于2018年11月被Firmenich收购。从2006年7月到2014年3月，Twomey先生还担任CadencePharmaceuticals，Inc.的董事兼审计委员会主席，该公司是一家专业制药公司，于2014年被马林克罗制药有限公司收购。Twomey先生在加州大学圣巴巴拉分校（University of California at Santa Barbara）获得商业经济学学士学位。
- Christopher Twomey,has served on Bionano Genomics, Inc. board of directors since July 2018. Since August 2013, Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a public medical device company. From March 1990 to June 2007, Mr. Twomey served in various roles, including as Senior Vice President, Finance and Chief Financial Officer, at Biosite Incorporated, a medical diagnostics company. From October 1981 to March 1990, Mr. Twomey served as an audit manager for Ernst & Young, LLP. Mr. Twomey served as a director of Senomyx, Inc., a taste technologies company, from March 2006 to November 2018 (when it was acquired by Firmenich SA). From July 2006 to March 2014, Mr. Twomey also served as a director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey received his B.A. in Business Economics from the University of California at Santa Barbara.
- Hannah Mamuszka
-
Hannah Mamuszka自2020年5月起担任我们的董事会成员。自2016年3月起，Mamuszka女士一直担任Alva10的创始人兼首席执行官，该公司专注于在健康保险付款人和诊断公司之间建立合作伙伴关系。Mamuszka女士还于2019年4月至2020年5月担任Precision Care Alliance（一家非营利组织，专注于政策改革以促进诊断发展）的执行董事。此外，2010年12月至2015年6月，她担任Exosome Diagnostics，Inc.（一家开发液体活检测试的私营公司）业务发展和临床战略Vice President。在加入Exosome之前，Mamuszka女士担任Asuragen，Inc.的战略业务发展总监，该公司是一家专注于诊断和治疗的私人公司。Mamuszka从2005年1月到2010年1月担任多个董事级别职位，最近担任Oncotech Inc.制药服务全球主管，后被Exiqon A/S收购。Mamuszka女士此前曾在Arqule，Inc.、Millennium Pharmaceuticals Inc.、Organogenesis，Inc.和国家癌症研究所担任多个实验室职位。Mamuszka女士在马里兰大学帕克学院（University of Maryland at College Park）获得神经生物学和生理学学士学位，在哈佛大学（Harvard University）获得分子生物学硕士学位。
Hannah Mamuszka,has served on Bionano Genomics, Inc. board of directors since May 2020. Since March 2016, Ms. Mamuszka has served as Founder and Chief Executive Officer of Alva10, Inc., a private market access strategy firm. Ms. Mamuszka has also served as an advisory board member of Carolina Health Informatics Program (CHIP), an interdisciplinary research and training program at the University of North Carolina, since January 2021 and served as a member of the board of directors of Circle Cardiovascular Imaging Inc., a private cardiac imaging company, from May 2021 to June 2022 (when it was acquired by Thomas Bravo). Ms. Mamuszka also served as an Executive Director of Precision Care Alliance, a non-profit focused on policy reform to enable diagnostic development, from April 2019 to May 2020. Additionally, from December 2010 to June 2015, she served as Vice President of Business Development and Clinical Strategy at Exosome Diagnostics, Inc., a private company developing liquid biopsy tests. Prior to joining Exosome, Ms. Mamuszka served as Director of Strategic Business Development, Companion Diagnostics at Asuragen, Inc., a private company focused on diagnostics and therapeutics. From January 2005 to January 2010, Ms. Mamuszka served in various director level positions, most recently as Global Director for Pharmaceutical Services, at Oncotech Inc., then by acquisition, at Exiqon A/S. Ms. Mamuszka has previously held various laboratory positions at ArQule, Inc., Millennium Pharmaceuticals Inc., Organogenesis, Inc. and the National Cancer Institute. Ms. Mamuszka received her B.S. in neurobiology and physiology from the University of Maryland at College Park and her M.S. in molecular biology from Harvard University. - Hannah Mamuszka自2020年5月起担任我们的董事会成员。自2016年3月起，Mamuszka女士一直担任Alva10的创始人兼首席执行官，该公司专注于在健康保险付款人和诊断公司之间建立合作伙伴关系。Mamuszka女士还于2019年4月至2020年5月担任Precision Care Alliance（一家非营利组织，专注于政策改革以促进诊断发展）的执行董事。此外，2010年12月至2015年6月，她担任Exosome Diagnostics，Inc.（一家开发液体活检测试的私营公司）业务发展和临床战略Vice President。在加入Exosome之前，Mamuszka女士担任Asuragen，Inc.的战略业务发展总监，该公司是一家专注于诊断和治疗的私人公司。Mamuszka从2005年1月到2010年1月担任多个董事级别职位，最近担任Oncotech Inc.制药服务全球主管，后被Exiqon A/S收购。Mamuszka女士此前曾在Arqule，Inc.、Millennium Pharmaceuticals Inc.、Organogenesis，Inc.和国家癌症研究所担任多个实验室职位。Mamuszka女士在马里兰大学帕克学院（University of Maryland at College Park）获得神经生物学和生理学学士学位，在哈佛大学（Harvard University）获得分子生物学硕士学位。
- Hannah Mamuszka,has served on Bionano Genomics, Inc. board of directors since May 2020. Since March 2016, Ms. Mamuszka has served as Founder and Chief Executive Officer of Alva10, Inc., a private market access strategy firm. Ms. Mamuszka has also served as an advisory board member of Carolina Health Informatics Program (CHIP), an interdisciplinary research and training program at the University of North Carolina, since January 2021 and served as a member of the board of directors of Circle Cardiovascular Imaging Inc., a private cardiac imaging company, from May 2021 to June 2022 (when it was acquired by Thomas Bravo). Ms. Mamuszka also served as an Executive Director of Precision Care Alliance, a non-profit focused on policy reform to enable diagnostic development, from April 2019 to May 2020. Additionally, from December 2010 to June 2015, she served as Vice President of Business Development and Clinical Strategy at Exosome Diagnostics, Inc., a private company developing liquid biopsy tests. Prior to joining Exosome, Ms. Mamuszka served as Director of Strategic Business Development, Companion Diagnostics at Asuragen, Inc., a private company focused on diagnostics and therapeutics. From January 2005 to January 2010, Ms. Mamuszka served in various director level positions, most recently as Global Director for Pharmaceutical Services, at Oncotech Inc., then by acquisition, at Exiqon A/S. Ms. Mamuszka has previously held various laboratory positions at ArQule, Inc., Millennium Pharmaceuticals Inc., Organogenesis, Inc. and the National Cancer Institute. Ms. Mamuszka received her B.S. in neurobiology and physiology from the University of Maryland at College Park and her M.S. in molecular biology from Harvard University.
- Yvonne Linney
-
Yvonne Linney自2020年5月起担任我们的董事会成员。自2019年1月以来，Linney博士一直担任生命科学行业咨询和战略开发公司Linney BioConsulting的负责人。Linney博士曾担任General Automation Laboratory Technologies Inc.的战略顾问。Galt自2019年11月起SRI International自2019年6月起加利福尼亚生命科学研究所自2019年3月起以及Tag.Bio，Inc.自2019年1月起。从2017年1月至2018年11月，Linney博士担任Transcriptic Inc.（现为Strateos，Inc.）的首席执行官，这是一家开发机器人云实验室平台的私人公司，她此前曾担任首席运营官（2015年10月以来）。Linney博士还于2016年12月至2018年11月在Transcriptic’；的董事会任职。此外，2006年11月至2015年1月，Linney博士担任公共生命科学和诊断公司安捷伦科技公司的执行Vice President兼生命科学总经理。在加入安捷伦之前，Linney博士从2005年到2006年担任拜耳诊断公司（现为西门子梦百合的一部分）的分子诊断和全球战略营销总监，从2003年到2005年担任Caliper Life Sciences的营销和产品管理高级总监。Linney博士还从1993年到2003年担任Amersham International（现GE梦百合）基因组学主任。Linney博士拥有英国沃里克大学（Warwick University）微生物学和病毒学学士学位，以及英国莱斯特大学（Leicester University）遗传学博士学位。
Yvonne Linney,has served on Bionano Genomics, Inc. board of directors since May 2020. Since January 2019, Dr. Linney has served as Principal at Linney BioConsulting, a private strategy development firm. Dr. Linney has also served as a member of the board of Sengenics Corporation, a private company developing tools for immunoprofiling for biodiscovery since January 2023. From January 2021 to September 2022, Dr. Linney served as Chief Operating Officer and member of the board of directors of Artificial, Inc., a private laboratory automation optimization software company, where she also served as a strategic advisor from September 2020 to January 2021. Dr. Linney has also served as a strategic advisor at the California Life Sciences Institute, a private life sciences membership organization, since March 2019, as a Boardroom Ready Member at Women in Bio, a private professional organization, since July 2019, and as a strategic advisor at Tag.bio, a private data science platform company, since January 2019. From December 2016 to November 2018, Dr. Linney served as the Chief Executive Officer and member of the board of directors of Transcriptic, Inc. (now Strateos, Inc.), a private robotic and cloud laboratory platform company, where she had previously served as Chief Operating Officer since October 2015. In addition, from November 2006 to January 2015, Dr. Linney served as Executive Vice President and General Manager, Life Science Solutions at Agilent Technologies, Inc., a public life sciences and diagnostics company. Prior to joining Agilent, Dr. Linney served as Director of Molecular Diagnostics and Global Strategic Marketing at Bayer Diagnostics (now part of Siemens Healthcare) from 2005 to 2006 and Senior Director, Marketing and Product Management at Caliper Life Sciences from 2003 to 2005. Dr. Linney holds a B.S. in Microbiology and Virology from Warwick University, UK, and a Ph.D. in Genetics from Leicester University, UK. - Yvonne Linney自2020年5月起担任我们的董事会成员。自2019年1月以来，Linney博士一直担任生命科学行业咨询和战略开发公司Linney BioConsulting的负责人。Linney博士曾担任General Automation Laboratory Technologies Inc.的战略顾问。Galt自2019年11月起SRI International自2019年6月起加利福尼亚生命科学研究所自2019年3月起以及Tag.Bio，Inc.自2019年1月起。从2017年1月至2018年11月，Linney博士担任Transcriptic Inc.（现为Strateos，Inc.）的首席执行官，这是一家开发机器人云实验室平台的私人公司，她此前曾担任首席运营官（2015年10月以来）。Linney博士还于2016年12月至2018年11月在Transcriptic’；的董事会任职。此外，2006年11月至2015年1月，Linney博士担任公共生命科学和诊断公司安捷伦科技公司的执行Vice President兼生命科学总经理。在加入安捷伦之前，Linney博士从2005年到2006年担任拜耳诊断公司（现为西门子梦百合的一部分）的分子诊断和全球战略营销总监，从2003年到2005年担任Caliper Life Sciences的营销和产品管理高级总监。Linney博士还从1993年到2003年担任Amersham International（现GE梦百合）基因组学主任。Linney博士拥有英国沃里克大学（Warwick University）微生物学和病毒学学士学位，以及英国莱斯特大学（Leicester University）遗传学博士学位。
- Yvonne Linney,has served on Bionano Genomics, Inc. board of directors since May 2020. Since January 2019, Dr. Linney has served as Principal at Linney BioConsulting, a private strategy development firm. Dr. Linney has also served as a member of the board of Sengenics Corporation, a private company developing tools for immunoprofiling for biodiscovery since January 2023. From January 2021 to September 2022, Dr. Linney served as Chief Operating Officer and member of the board of directors of Artificial, Inc., a private laboratory automation optimization software company, where she also served as a strategic advisor from September 2020 to January 2021. Dr. Linney has also served as a strategic advisor at the California Life Sciences Institute, a private life sciences membership organization, since March 2019, as a Boardroom Ready Member at Women in Bio, a private professional organization, since July 2019, and as a strategic advisor at Tag.bio, a private data science platform company, since January 2019. From December 2016 to November 2018, Dr. Linney served as the Chief Executive Officer and member of the board of directors of Transcriptic, Inc. (now Strateos, Inc.), a private robotic and cloud laboratory platform company, where she had previously served as Chief Operating Officer since October 2015. In addition, from November 2006 to January 2015, Dr. Linney served as Executive Vice President and General Manager, Life Science Solutions at Agilent Technologies, Inc., a public life sciences and diagnostics company. Prior to joining Agilent, Dr. Linney served as Director of Molecular Diagnostics and Global Strategic Marketing at Bayer Diagnostics (now part of Siemens Healthcare) from 2005 to 2006 and Senior Director, Marketing and Product Management at Caliper Life Sciences from 2003 to 2005. Dr. Linney holds a B.S. in Microbiology and Virology from Warwick University, UK, and a Ph.D. in Genetics from Leicester University, UK.
- Vincent J. Wong
-
Vincent J. Wong，自2021年12月起担任Bionano Genomics公司董事会成员。自2021年3月以来，黄先生一直担任Geneoscopy，Inc.的首席商务官，这是一家开发胃肠道健康诊断测试的私营公司。自2021年3月起，黄之锋还担任印第安纳大学附属机构IU Ventures的驻所高管，为投资组合初创公司提供咨询服务。从2005年4月至2020年12月，黄先生曾在罗氏诊断公司、罗氏控股公司的诊断部门及其附属实体担任多个领导职务，包括销售副总裁、护理点诊断副总裁、医生办公室和专科诊断副总裁，以及战略和传播副总裁。黄先生拥有圣母大学经济学和政府学学士学位、印第安纳大学毛雷尔法学院法学博士学位和西北大学家乐氏管理学院工商管理硕士学位。
Vincent J. Wong,has served on Bionano Genomics, Inc. board of directors since December 2021. Since March 2021, Mr. Wong has served as Chief Commercial Officer at Geneoscopy, Inc., a private company developing diagnostic tests for gastrointestinal health. Mr. Wong has also served as an Executive in Residence at IU Ventures, an affiliate of Indiana University advising portfolio start-up companies, since March 2021. From April 2005 to December 2020, Mr. Wong served in various leadership roles at Roche Diagnostics Corporation, the diagnostics division of Roche Holding AG and its affiliated entities, including as Vice President of Sales, Point of Care Diagnostics, Vice President, Physician Office and Specialty Diagnostics, and Vice President, Strategy and Communications. Mr. Wong holds a B.A. in Economics and Government from the University of Notre Dame, a J.D. from Indiana University Maurer School of Law and an MBA from Northwestern University's Kellogg School of Management. - Vincent J. Wong，自2021年12月起担任Bionano Genomics公司董事会成员。自2021年3月以来，黄先生一直担任Geneoscopy，Inc.的首席商务官，这是一家开发胃肠道健康诊断测试的私营公司。自2021年3月起，黄之锋还担任印第安纳大学附属机构IU Ventures的驻所高管，为投资组合初创公司提供咨询服务。从2005年4月至2020年12月，黄先生曾在罗氏诊断公司、罗氏控股公司的诊断部门及其附属实体担任多个领导职务，包括销售副总裁、护理点诊断副总裁、医生办公室和专科诊断副总裁，以及战略和传播副总裁。黄先生拥有圣母大学经济学和政府学学士学位、印第安纳大学毛雷尔法学院法学博士学位和西北大学家乐氏管理学院工商管理硕士学位。
- Vincent J. Wong,has served on Bionano Genomics, Inc. board of directors since December 2021. Since March 2021, Mr. Wong has served as Chief Commercial Officer at Geneoscopy, Inc., a private company developing diagnostic tests for gastrointestinal health. Mr. Wong has also served as an Executive in Residence at IU Ventures, an affiliate of Indiana University advising portfolio start-up companies, since March 2021. From April 2005 to December 2020, Mr. Wong served in various leadership roles at Roche Diagnostics Corporation, the diagnostics division of Roche Holding AG and its affiliated entities, including as Vice President of Sales, Point of Care Diagnostics, Vice President, Physician Office and Specialty Diagnostics, and Vice President, Strategy and Communications. Mr. Wong holds a B.A. in Economics and Government from the University of Notre Dame, a J.D. from Indiana University Maurer School of Law and an MBA from Northwestern University's Kellogg School of Management.
- Aleksandar Rajkovic
-
Aleksandar Rajkovic，自2022年2月起担任Bionano Genomics公司董事会成员。自2018年5月起，Rajkovic博士担任加州大学旧金山分校（“加州大学旧金山分校”）首席基因组学官兼基因组医学计划主任。Rajkovic博士还担任加州大学旧金山分校卫生系统遗传和基因组医学中心的医学主任和主任，担任加州大学旧金山分校的Stuart Lindsay实验病理学特聘教授，自2020年4月起担任美国医学学会遗传学基金会的董事会成员，自2022年2月起担任私营基因组学软件公司Allelica的科学顾问委员会成员。从2009年7月到2018年5月，拉伊科维奇博士在匹兹堡大学医学中心的玛吉妇女医院担任马库斯·艾伦·霍格生殖科学讲座和生殖遗传学主任。Rajkovic博士拥有约翰·霍普金斯大学的化学学士学位和凯斯西储大学的分子生物学的医学博士和博士学位。
Aleksandar Rajkovic,has served on Bionano Genomics, Inc. board of directors since February 2022. Since May 2018, Dr. Rajkovic has served as Chief Genomics Officer and Director of the Genomic Medicine Initiative at University of California San Francisco ("UCSF"). Dr. Rajkovic also serves as Medical Director and Chief of the Center for Genetic and Genomic Medicine for the UCSF Health System, serves as the Stuart Lindsay Distinguished Professor in Experimental Pathology at UCSF, serves on the board of directors for the American College of Medical Genetics Foundation, since April 2020, and on the scientific advisory board of Allelica, a private genomics software company, since February 2022. From July 2009 to May 2018, Dr. Rajkovic served as the Marcus Allen Hogge Chair in Reproductive Sciences and director of reproductive genetics at the Magee-Womens Hospital at University of Pittsburgh Medical Center. Dr. Rajkovic holds a B.S. in Chemistry from Johns Hopkins University and an M.D. and Ph.D. in Molecular Biology from Case Western Reserve University. - Aleksandar Rajkovic，自2022年2月起担任Bionano Genomics公司董事会成员。自2018年5月起，Rajkovic博士担任加州大学旧金山分校（“加州大学旧金山分校”）首席基因组学官兼基因组医学计划主任。Rajkovic博士还担任加州大学旧金山分校卫生系统遗传和基因组医学中心的医学主任和主任，担任加州大学旧金山分校的Stuart Lindsay实验病理学特聘教授，自2020年4月起担任美国医学学会遗传学基金会的董事会成员，自2022年2月起担任私营基因组学软件公司Allelica的科学顾问委员会成员。从2009年7月到2018年5月，拉伊科维奇博士在匹兹堡大学医学中心的玛吉妇女医院担任马库斯·艾伦·霍格生殖科学讲座和生殖遗传学主任。Rajkovic博士拥有约翰·霍普金斯大学的化学学士学位和凯斯西储大学的分子生物学的医学博士和博士学位。
- Aleksandar Rajkovic,has served on Bionano Genomics, Inc. board of directors since February 2022. Since May 2018, Dr. Rajkovic has served as Chief Genomics Officer and Director of the Genomic Medicine Initiative at University of California San Francisco ("UCSF"). Dr. Rajkovic also serves as Medical Director and Chief of the Center for Genetic and Genomic Medicine for the UCSF Health System, serves as the Stuart Lindsay Distinguished Professor in Experimental Pathology at UCSF, serves on the board of directors for the American College of Medical Genetics Foundation, since April 2020, and on the scientific advisory board of Allelica, a private genomics software company, since February 2022. From July 2009 to May 2018, Dr. Rajkovic served as the Marcus Allen Hogge Chair in Reproductive Sciences and director of reproductive genetics at the Magee-Womens Hospital at University of Pittsburgh Medical Center. Dr. Rajkovic holds a B.S. in Chemistry from Johns Hopkins University and an M.D. and Ph.D. in Molecular Biology from Case Western Reserve University.
- David L. Barker
-
David L. Barker，博士，自2006年11月起担任Bionano Genomics, Inc.的董事。2000年至2006年，Barker博士是Illumina, Inc.的副总裁和首席科学官。1998年至2000年，Barker博士是Amersham Biosciences, Inc.（现为General Electric Company的一部分）的副总裁和首席科学顾问。在他进入商界之前，Barker博士在Harvard Medical School担任神经生物学学科研究员，和the University of Oregon和Oregon State University的助教。 Barker博士也是BioNano Genomics, Inc., Integrated Diagnostics Inc., IntegenX Inc.和AmideBio, Inc.的董事，和Illumina的科学顾问。 Barker博士获得了Brandeis University的生物化学博士学位，和the California Institute of Technology的化学荣誉学士学位。
David L. Barker,has served on Bionano Genomics, Inc. board of directors since May 2010, and as Chairman of Bionano Genomics, Inc. board of directors since August 2016. Dr. Barker has also served as a member of the board of directors of AmideBio, LLC, a private biotechnology company, since August 2011, and of Singular Genomics Systems, Inc., a public life science technology company, since June 2016. He has also served as a scientific advisor to LunaPBC, a public benefit corporation, since November 2017. Dr. Barker previously served as a member of the board of directors of Aspen Neuroscience, a private cell therapy company, from October 2018 to May 2021, IntegenX, Inc., a private DNA testing technology company, from June 2006 to March 2018 (when it was acquired by Thermo Fisher Scientific), and of Integrated Diagnostics, Inc., a private molecular diagnostics company, from October 2009 to August 2018 (when it was acquired by Biodesix, Inc.). He served as Vice President and Chief Scientific Officer at Illumina, Inc. ("Illumina") from 2000 to 2007, and on the Illumina scientific advisory board until May 2016. Dr. Barker was previously a member of the board of directors of NextBio, Inc. (acquired by Illumina in 2013), ProteinSimple, Inc. (acquired by Bio-Techne Corporation ("BT") in 2014) and Zephyrus Biosciences, Inc. (acquired by BT in 2016). Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of GE Healthcare. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a B.S. with honors in Chemistry from the California Institute of Technology and a Ph.D. in Biochemistry from Brandeis University. - David L. Barker，博士，自2006年11月起担任Bionano Genomics, Inc.的董事。2000年至2006年，Barker博士是Illumina, Inc.的副总裁和首席科学官。1998年至2000年，Barker博士是Amersham Biosciences, Inc.（现为General Electric Company的一部分）的副总裁和首席科学顾问。在他进入商界之前，Barker博士在Harvard Medical School担任神经生物学学科研究员，和the University of Oregon和Oregon State University的助教。 Barker博士也是BioNano Genomics, Inc., Integrated Diagnostics Inc., IntegenX Inc.和AmideBio, Inc.的董事，和Illumina的科学顾问。 Barker博士获得了Brandeis University的生物化学博士学位，和the California Institute of Technology的化学荣誉学士学位。
- David L. Barker,has served on Bionano Genomics, Inc. board of directors since May 2010, and as Chairman of Bionano Genomics, Inc. board of directors since August 2016. Dr. Barker has also served as a member of the board of directors of AmideBio, LLC, a private biotechnology company, since August 2011, and of Singular Genomics Systems, Inc., a public life science technology company, since June 2016. He has also served as a scientific advisor to LunaPBC, a public benefit corporation, since November 2017. Dr. Barker previously served as a member of the board of directors of Aspen Neuroscience, a private cell therapy company, from October 2018 to May 2021, IntegenX, Inc., a private DNA testing technology company, from June 2006 to March 2018 (when it was acquired by Thermo Fisher Scientific), and of Integrated Diagnostics, Inc., a private molecular diagnostics company, from October 2009 to August 2018 (when it was acquired by Biodesix, Inc.). He served as Vice President and Chief Scientific Officer at Illumina, Inc. ("Illumina") from 2000 to 2007, and on the Illumina scientific advisory board until May 2016. Dr. Barker was previously a member of the board of directors of NextBio, Inc. (acquired by Illumina in 2013), ProteinSimple, Inc. (acquired by Bio-Techne Corporation ("BT") in 2014) and Zephyrus Biosciences, Inc. (acquired by BT in 2016). Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of GE Healthcare. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a B.S. with honors in Chemistry from the California Institute of Technology and a Ph.D. in Biochemistry from Brandeis University.
高管简历
中英对照 | 中文 | 英文- R. Erik Holmlin
R.Erik Holmlin自2011年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。Holmlin从2010年6月到2011年2月担任GenVault Corporation（一家私人生物样本管理解决方案公司）总裁和首席执行官。此前，Holmlin博士曾担任Domain Associates（一家专注的生命科学风险投资公司）的常驻企业家；Exiqon A/S（一家公开上市的RNA研究解决方案公司）的首席商务官；它被Becton Dickinson and Company收购；以及Harvard University的国家卫生研究院博士后研究员。直到2016年6月，Holmlin博士担任Nanosphere，Inc.的董事，该公司是一家公开上市的分子诊断公司，随后被公开上市的生物测试公司路明克斯公司收购。Holmlin博士在西方学院（Occidental College）获得化学学士学位，在加州理工学院（California Institute of Technology）获得化学博士学位，在加州大学伯克利分校（University of California，Berkeley）和哥伦比亚大学（Columbia University）获得MBA学位。
R. Erik Holmlin,has served as Bionano Genomics, Inc. President and Chief Executive Officer and as a member of Bionano Genomics, Inc. board of directors since January 2011. Dr. Holmlin has also served as a member of the board of directors of Innovatus Life Sciences Acquisition Corp, a blank check company seeking to effect a business combination with one or more businesses, since March 2021. From June 2010 to February 2011, Dr. Holmlin served as president and Chief Executive Officer of GenVault Corporation, a private biosample management solutions company. Previously, Dr. Holmlin held positions as an entrepreneur in residence at Domain Associates, LLC, a dedicated life sciences venture capital firm; Chief Commercial Officer of Exiqon A/S, a publicly traded RNA research solutions company; founder and executive at GeneOhm Sciences, Inc., which was acquired by Becton, Dickinson and Company; and a National Institutes of Health postdoctoral fellow at Harvard University. Dr. Holmlin received his B.S. in Chemistry from Occidental College, his Ph.D. in Chemistry from the California Institute of Technology and MBAs from University of California, Berkeley and Columbia University.- R.Erik Holmlin自2011年1月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。Holmlin从2010年6月到2011年2月担任GenVault Corporation（一家私人生物样本管理解决方案公司）总裁和首席执行官。此前，Holmlin博士曾担任Domain Associates（一家专注的生命科学风险投资公司）的常驻企业家；Exiqon A/S（一家公开上市的RNA研究解决方案公司）的首席商务官；它被Becton Dickinson and Company收购；以及Harvard University的国家卫生研究院博士后研究员。直到2016年6月，Holmlin博士担任Nanosphere，Inc.的董事，该公司是一家公开上市的分子诊断公司，随后被公开上市的生物测试公司路明克斯公司收购。Holmlin博士在西方学院（Occidental College）获得化学学士学位，在加州理工学院（California Institute of Technology）获得化学博士学位，在加州大学伯克利分校（University of California，Berkeley）和哥伦比亚大学（Columbia University）获得MBA学位。
- R. Erik Holmlin,has served as Bionano Genomics, Inc. President and Chief Executive Officer and as a member of Bionano Genomics, Inc. board of directors since January 2011. Dr. Holmlin has also served as a member of the board of directors of Innovatus Life Sciences Acquisition Corp, a blank check company seeking to effect a business combination with one or more businesses, since March 2021. From June 2010 to February 2011, Dr. Holmlin served as president and Chief Executive Officer of GenVault Corporation, a private biosample management solutions company. Previously, Dr. Holmlin held positions as an entrepreneur in residence at Domain Associates, LLC, a dedicated life sciences venture capital firm; Chief Commercial Officer of Exiqon A/S, a publicly traded RNA research solutions company; founder and executive at GeneOhm Sciences, Inc., which was acquired by Becton, Dickinson and Company; and a National Institutes of Health postdoctoral fellow at Harvard University. Dr. Holmlin received his B.S. in Chemistry from Occidental College, his Ph.D. in Chemistry from the California Institute of Technology and MBAs from University of California, Berkeley and Columbia University.
- Mark Oldakowski
Mark Oldakowski自2017年11月起担任我们的首席运营官，此前自2014年10月起担任我们的Vice President，产品开发和运营。从2011年12月到2014年8月，Oldakowski先生担任Brooks Life Science Systems的工程高级总监兼首席产品官，这是一家为生命科学行业提供自动化和低温解决方案的提供商，2009年4月至2011年10月，担任私人生命科学系统公司赛默飞世尔科技（Thermo Fisher Scientific）的工程总监，该公司于2016年3月被Affymetrix，Inc.收购。Oldakowski从2007年12月到2009年4月担任Siemens梦百合Diagnostics高级经理和研发核心团队负责人，在过去的13年里，他在Applied Biosystems（现为Thermo Fisher Scientific的一部分）开发测序和实时PCR系统。Oldakowski先生在伦斯勒理工学院（Rensselaer Polytechnic Institute）获得电气工程学士学位和计算机与系统工程硕士学位。
Mark Oldakowski,has served as Bionano Genomics, Inc. Chief Operating Officer since November 2017 and previously served as Bionano Genomics, Inc. Vice President, Product Development and Operations since October 2014. Mr. Oldakowski previously served as the Senior Director of Engineering and Chief Product Officer at Brooks Life Science Systems (currently Azenta Life Sciences), a private automation and cryogenic solutions company, from December 2011 to August 2014, and as a Director of Engineering at Affymetrix, Inc. (now Applied Biosystems), a private life science systems company, from April 2009 to October 2011. From December 2007 to April 2009, Mr. Oldakowski served as a Senior Manager and Core Team Leader of R&D for Siemens Healthcare Diagnostics, and for the prior 13 years, he developed sequencing and real-time PCR systems at Applied Biosystems, now a part of Thermo Fisher Scientific. Mr. Oldakowski received both his B.S. in Electrical Engineering and his M.S. in Computer and Systems Engineering from Rensselaer Polytechnic Institute.- Mark Oldakowski自2017年11月起担任我们的首席运营官，此前自2014年10月起担任我们的Vice President，产品开发和运营。从2011年12月到2014年8月，Oldakowski先生担任Brooks Life Science Systems的工程高级总监兼首席产品官，这是一家为生命科学行业提供自动化和低温解决方案的提供商，2009年4月至2011年10月，担任私人生命科学系统公司赛默飞世尔科技（Thermo Fisher Scientific）的工程总监，该公司于2016年3月被Affymetrix，Inc.收购。Oldakowski从2007年12月到2009年4月担任Siemens梦百合Diagnostics高级经理和研发核心团队负责人，在过去的13年里，他在Applied Biosystems（现为Thermo Fisher Scientific的一部分）开发测序和实时PCR系统。Oldakowski先生在伦斯勒理工学院（Rensselaer Polytechnic Institute）获得电气工程学士学位和计算机与系统工程硕士学位。
- Mark Oldakowski,has served as Bionano Genomics, Inc. Chief Operating Officer since November 2017 and previously served as Bionano Genomics, Inc. Vice President, Product Development and Operations since October 2014. Mr. Oldakowski previously served as the Senior Director of Engineering and Chief Product Officer at Brooks Life Science Systems (currently Azenta Life Sciences), a private automation and cryogenic solutions company, from December 2011 to August 2014, and as a Director of Engineering at Affymetrix, Inc. (now Applied Biosystems), a private life science systems company, from April 2009 to October 2011. From December 2007 to April 2009, Mr. Oldakowski served as a Senior Manager and Core Team Leader of R&D for Siemens Healthcare Diagnostics, and for the prior 13 years, he developed sequencing and real-time PCR systems at Applied Biosystems, now a part of Thermo Fisher Scientific. Mr. Oldakowski received both his B.S. in Electrical Engineering and his M.S. in Computer and Systems Engineering from Rensselaer Polytechnic Institute.
- Gulsen Kama
Gulsen Kama在业务规划和执行方面拥有广泛的背景，尤其是在需要严格管理费用以实现盈利增长的运营环境中。她最近在Northern Data AG担任首席财务官，在那里她创建并实施了一个全球金融组织，以实现强劲增长。在加入Northern Data AG之前，Kama女士曾在Quest最大的地区奎斯特诊疗担任东部地区和医疗IT 首席财务官，在那里她推动了市场扩张和运营效率。在加入Quest之前，卡玛女士在联邦快递、联合航空、A & P和AIG等价值数十亿美元的组织建立了令人印象深刻的变革和增长导向型领导记录，她在战略规划、财务规划和分析、资本规划和公司战略方面担任高级领导职务。
Gulsen Kama,has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northern Data AG, Ms. Kama was Chief Financial Officer, East Region and Healthcare IT at Quest Diagnostics, Quest's largest region, where she drove market expansion and operational efficiencies. Before Quest, Ms. Kama established an impressive track record of transformative and growth-oriented leadership across a diverse range of multibillion-dollar organizations, including FedEx, United Airlines, A&P, and AIG, where she held senior leadership roles in strategic planning, financial planning and analysis, capital planning and corporate strategy.- Gulsen Kama在业务规划和执行方面拥有广泛的背景，尤其是在需要严格管理费用以实现盈利增长的运营环境中。她最近在Northern Data AG担任首席财务官，在那里她创建并实施了一个全球金融组织，以实现强劲增长。在加入Northern Data AG之前，Kama女士曾在Quest最大的地区奎斯特诊疗担任东部地区和医疗IT 首席财务官，在那里她推动了市场扩张和运营效率。在加入Quest之前，卡玛女士在联邦快递、联合航空、A & P和AIG等价值数十亿美元的组织建立了令人印象深刻的变革和增长导向型领导记录，她在战略规划、财务规划和分析、资本规划和公司战略方面担任高级领导职务。
- Gulsen Kama,has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northern Data AG, Ms. Kama was Chief Financial Officer, East Region and Healthcare IT at Quest Diagnostics, Quest's largest region, where she drove market expansion and operational efficiencies. Before Quest, Ms. Kama established an impressive track record of transformative and growth-oriented leadership across a diverse range of multibillion-dollar organizations, including FedEx, United Airlines, A&P, and AIG, where she held senior leadership roles in strategic planning, financial planning and analysis, capital planning and corporate strategy.
- Alka Chaubey
Alka Chaubey，自2020年8月起担任Bionano Genomics, Inc.首席医疗官。Chaubey博士还自2016年8月起担任癌症基因组学联盟的董事会成员，该联盟是一家专注于临床癌症基因组学的非营利组织，自2021年3月起担任美国医学遗传学和基因组学委员会多样性、公平和包容委员会的成员，并担任专注于分子诊断的非营利组织分子病理学协会的遗传学细分提名委员会代表，任期至2021年7月。Chaubey博士于2018年5月至2020年8月担任珀金埃尔默基因组学的细胞基因组学主管，该公司是上市公司珀金埃尔默公司的子公司，专注于基因和基因组测试，在那里她领导了几个创新产品的成功开发和发布，包括CNGnome测试（低通路全基因组测序），以及利用Saphyr的新的FSHD检测。她还在珀金埃尔默的Vanadis团队中发挥了不可或缺的作用，他们努力将一种新的不含PCR-的NIPT技术推向市场。在加入珀金埃尔默基因组学之前，Chaubey博士于2013年8月至2020年8月担任非营利性基因诊断机构格林伍德基因中心细胞基因组学实验室主任，并于2010年8月至2013年8月担任助理主任。Chaubey博士还担任学术职务，担任乔治亚密教和分子实验室的科学主任，奥古斯塔大学医学中心细胞遗传学实验室的科学主任，以及奥古斯塔大学乔治亚医学院病理学兼职助理教授。Chaubey博士在印度阿姆利则的Guru Nanak Dev大学获得博士学位，并在印度海得拉巴的细胞和分子生物学中心和伊利诺伊大学芝加哥分校完成博士后研究。
Alka Chaubey,has served as Bionano Genomics, Inc. Chief Medical Officer since August 2020. Dr. Chaubey has also served on the board of directors of the Cancer Genomics Consortium, a nonprofit organization focusing on clinical cancer genomics, since August 2016, as a member of the Diversity, Equity and Inclusion Committee of the American Board of Medical Genetics and Genomics, since March 2021, and as the Genetics Subdivision Nominating Committee representative of the Association for Molecular Pathology, a nonprofit organization focusing on molecular diagnostics, until July 2021. Dr. Chaubey served as the Head of Cytogenomics at PerkinElmer Genomics, a subsidiary of the public company PerkinElmer, Inc. focused on genetic and genomic testing, from May 2018 to August 2020, where she led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr.Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center, a nonprofit genetic diagnostic institute, from August 2013 to August 2020, where she also served as an Assistant Director from August 2010 to August 2013. Dr. Chaubey also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant professor of Pathology of the Medical College of Georgia at Augusta University. Dr. Chaubey received her Ph.D. from Guru Nanak Dev University, Amritsar, India and completed her post-doctoral studies at Center for Cellular and Molecular Biology, Hyderabad, India, and University of Illinois at Chicago.- Alka Chaubey，自2020年8月起担任Bionano Genomics, Inc.首席医疗官。Chaubey博士还自2016年8月起担任癌症基因组学联盟的董事会成员，该联盟是一家专注于临床癌症基因组学的非营利组织，自2021年3月起担任美国医学遗传学和基因组学委员会多样性、公平和包容委员会的成员，并担任专注于分子诊断的非营利组织分子病理学协会的遗传学细分提名委员会代表，任期至2021年7月。Chaubey博士于2018年5月至2020年8月担任珀金埃尔默基因组学的细胞基因组学主管，该公司是上市公司珀金埃尔默公司的子公司，专注于基因和基因组测试，在那里她领导了几个创新产品的成功开发和发布，包括CNGnome测试（低通路全基因组测序），以及利用Saphyr的新的FSHD检测。她还在珀金埃尔默的Vanadis团队中发挥了不可或缺的作用，他们努力将一种新的不含PCR-的NIPT技术推向市场。在加入珀金埃尔默基因组学之前，Chaubey博士于2013年8月至2020年8月担任非营利性基因诊断机构格林伍德基因中心细胞基因组学实验室主任，并于2010年8月至2013年8月担任助理主任。Chaubey博士还担任学术职务，担任乔治亚密教和分子实验室的科学主任，奥古斯塔大学医学中心细胞遗传学实验室的科学主任，以及奥古斯塔大学乔治亚医学院病理学兼职助理教授。Chaubey博士在印度阿姆利则的Guru Nanak Dev大学获得博士学位，并在印度海得拉巴的细胞和分子生物学中心和伊利诺伊大学芝加哥分校完成博士后研究。
- Alka Chaubey,has served as Bionano Genomics, Inc. Chief Medical Officer since August 2020. Dr. Chaubey has also served on the board of directors of the Cancer Genomics Consortium, a nonprofit organization focusing on clinical cancer genomics, since August 2016, as a member of the Diversity, Equity and Inclusion Committee of the American Board of Medical Genetics and Genomics, since March 2021, and as the Genetics Subdivision Nominating Committee representative of the Association for Molecular Pathology, a nonprofit organization focusing on molecular diagnostics, until July 2021. Dr. Chaubey served as the Head of Cytogenomics at PerkinElmer Genomics, a subsidiary of the public company PerkinElmer, Inc. focused on genetic and genomic testing, from May 2018 to August 2020, where she led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr.Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center, a nonprofit genetic diagnostic institute, from August 2013 to August 2020, where she also served as an Assistant Director from August 2010 to August 2013. Dr. Chaubey also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant professor of Pathology of the Medical College of Georgia at Augusta University. Dr. Chaubey received her Ph.D. from Guru Nanak Dev University, Amritsar, India and completed her post-doctoral studies at Center for Cellular and Molecular Biology, Hyderabad, India, and University of Illinois at Chicago.
- Jonathan Dixon
Jonathan Dixon，自2023年3月起担任Bionano Genomics, Inc.总法律顾问，自2022年3月起担任Bionano Genomics, Inc.全球法律主管。2015年3月至2022年3月，Dixon先生在碧迪医疗公司担任知识产权协理总法律顾问。在此之前，Dixon先生于2013年6月至2015年3月担任CareFusion助理总法律顾问。2006年3月至2013年6月，他在碧迪医疗公司担任高级知识产权顾问。2003年6月至2006年3月，Dixon先生担任GeneOhm Sciences，Inc.法律事务主任，在此之前，他于2001年6月至2003年6月在国家卫生研究院担任技术转让干事。迪克森先生在杨百翰大学获得了微生物学和经济学学士学位，并在刘易斯和克拉克学院获得了法学博士学位。
Jonathan Dixon,has served as Bionano Genomics, Inc. General Counsel since March 2023, and as Bionano Genomics, Inc. Global Head of Legal since March 2022. From March 2015 to March 2022 Mr. Dixon served as Associate General Counsel, IP, at Becton, Dickinson and Company. Prior to this, Mr. Dixon served as Assistant General Counsel at CareFusion from June 2013 to March 2015. From March 2006 to June 2013, he served as Senior Intellectual Property Counsel at Becton, Dickinson and Company. From June 2003 to March 2006, Mr. Dixon served as Director, Legal Affairs at GeneOhm Sciences, Inc. Prior to this he served at the National Institutes of Health as Technology Transfer Officer from June 2001 to June 2003. Mr. Dixon received his B.S. in both Microbiology and Economics from Brigham Young University and received his J.D. from Lewis and Clark College.- Jonathan Dixon，自2023年3月起担任Bionano Genomics, Inc.总法律顾问，自2022年3月起担任Bionano Genomics, Inc.全球法律主管。2015年3月至2022年3月，Dixon先生在碧迪医疗公司担任知识产权协理总法律顾问。在此之前，Dixon先生于2013年6月至2015年3月担任CareFusion助理总法律顾问。2006年3月至2013年6月，他在碧迪医疗公司担任高级知识产权顾问。2003年6月至2006年3月，Dixon先生担任GeneOhm Sciences，Inc.法律事务主任，在此之前，他于2001年6月至2003年6月在国家卫生研究院担任技术转让干事。迪克森先生在杨百翰大学获得了微生物学和经济学学士学位，并在刘易斯和克拉克学院获得了法学博士学位。
- Jonathan Dixon,has served as Bionano Genomics, Inc. General Counsel since March 2023, and as Bionano Genomics, Inc. Global Head of Legal since March 2022. From March 2015 to March 2022 Mr. Dixon served as Associate General Counsel, IP, at Becton, Dickinson and Company. Prior to this, Mr. Dixon served as Assistant General Counsel at CareFusion from June 2013 to March 2015. From March 2006 to June 2013, he served as Senior Intellectual Property Counsel at Becton, Dickinson and Company. From June 2003 to March 2006, Mr. Dixon served as Director, Legal Affairs at GeneOhm Sciences, Inc. Prior to this he served at the National Institutes of Health as Technology Transfer Officer from June 2001 to June 2003. Mr. Dixon received his B.S. in both Microbiology and Economics from Brigham Young University and received his J.D. from Lewis and Clark College.